Pacira Pharmaceuticals (PCRX) stock plummeted 5.03% on Monday, following the news of a class action lawsuit filed against the company.
According to the report, a class action lawsuit was filed against Pacira Biosciences, Inc. (PCRX) by Levi & Korsinsky on January 13, 2025. The lawsuit alleges certain claims against the company and its executives, potentially posing legal and financial risks for Pacira Pharmaceuticals.
The market reacted negatively to the news, as investors seemingly expressed concern over the potential implications of the lawsuit on the company's operations and financial performance. The stock experienced a significant sell-off, resulting in a 5.03% decline in its share price on Monday.
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.